Chonluten

Bioregulators Research compound (not approved for human use)

Synthetic tripeptide bioregulator (Glu-Asp-Gly) · also known as EDG, Glu-Asp-Gly

For reference only — not medical advice. Figures are commonly reported values compiled from published sources and may be wrong or out of date. Many compounds listed are not approved for human use. Talk to a licensed clinician before using any compound.

Chonluten is a short bioregulator associated with respiratory tissue in the originating literature. Published findings are laboratory-based, and the escalating vial schedule here is a community convention.

Commonly reported dosing (20 mg vial)

Reconstituted with 3 mL → 6.667 mg/mL.

Phase	Dose	Volume	U-100 units
Starting	250 mcg	0.037 mL	3.8
Standard	1 mg	0.15 mL	15
Higher	4 mg	0.6 mL	60

Frequency: Once daily, subcutaneous (gradual escalation over 8-16 weeks, community-reported) · Half-life: Not well characterized in the published literature

Open in calculator

Commonly reported reconstitution steps

Vials are usually brought to room temperature (about 15-20 minutes) first.
3 mL of bacteriostatic water is added slowly down the inside wall of the 20 mg vial.
The vial is swirled gently until clear, not shaken.
This gives 6.67 mg/mL. Mixed vials are typically labeled with the date and refrigerated.

Storage

Before mixing: Lyophilized vials are commonly stored frozen (about -20 °C), dry, and protected from light.

After mixing: Reconstituted solution is commonly kept refrigerated (2-8 °C), protected from light, and freeze-thaw cycles are commonly avoided.

How it works

Reported to modulate proliferation and inflammatory signaling (ERK1/2 and STAT1 pathways) in cultured immune cells; how this relates to lung tissue is not established.

Researched for

Studied in human monocyte and macrophage cell lines, where it was reported to affect proliferation and lower inflammatory cytokine release after stimulation.
Described in reviews as a respiratory-tissue bioregulator.

Notes

Evidence comes largely from a single research group (Khavinson and colleagues, St. Petersburg), mostly cell-culture and animal work; independent replication and controlled human trials are scarce.
Published human work from the originating group has mostly used oral or other non-vial formats; the vial, reconstitution and dosing figures here reflect community-reported conventions rather than trial-validated regimens.
Not FDA-approved.
The listed amounts climb to several milligrams per day, far above the doses used in the cell experiments; those figures reflect community use only.

Sources

Last reviewed 2026-10-06.

Bronchogen

Synthetic tetrapeptide bioregulator (Ala-Glu-Asp-Leu)

Bronchogen is a four-residue peptide (alanine, glutamate, aspartate, leucine) studied by the Khavinson group as a regulator of airway tissue.

20 mg vial · Once daily, in 10- or 20-day courses (community-reported)

Vilon

Synthetic dipeptide bioregulator (Lys-Glu)

Vilon is the two-residue peptide lysine-glutamate (Lys-Glu), developed by the Khavinson group as a thymus-related immune bioregulator.

20 mg vial · Once daily for 5 consecutive days, then about 23 days off (community-reported)

Cartalax

Synthetic tripeptide bioregulator (Ala-Glu-Asp)

Cartalax is a three-residue peptide (alanine, glutamate, aspartate) studied by the Khavinson group in connection with cartilage and connective tissue.

20 mg vial · Once daily, subcutaneous (8-12 week courses, community-reported)